Completed

4

200

 

Subjects will receive up to 2 treatment cycles of HAG(homoharringtonine, low-dose cytarabine and granulocyte colony-stimulating factor (G-CSF)). Subjects who achieve a CR should continue therapy. Subjects who accept maintenane therapy would be randomized to the group A. The group A subjects would be treated by HAG and decitabine in turn for 6 cycles, then keep maintenane therapy by Melphalan ;Subjects will receive up to 2 treatment cycles of HAG (homoharringtonine, low-dose cytarabine and granulocyte colony-stimulating factor (G-CSF)). Subjects who achieve a CR should continue therapy. Subjects who accept maintenane therapy would be randomized to the control group. The group B subjects would be treated by 3 cycles of HAG, then keep maintenane therapy by Melphalan.

Institute of Hematology and Blood Diseases Hospital (IH), Chinese Academy of Medical Sciences (CAMS); Level of the institution：, no

myelodysplastic syndromes(MDS) RAEB

 

 

Completed

4

100

 

cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 ug/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0*10^9/L.

Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, SHDC12010202

high-risk MDS and AML transformed from MDS

 

 

Not yet recruiting

4

70

 

GCSF 300ug d0-d5, Cladribine 5mg/m2, d1-5, cytarabine 2g/m2 qd, d1-5, homoharringtonine 2mg/m2d1-d5. ;GCSF 300ug d0-d5, azacytidine 100mg, d1-5, cedarabine 10mg qd, d1-28, cytarabine 10mg/m2 q12h, d3-9, homoharringtonine 1mg d3-d9.

Sichuan People's Hospital; Sichuan People's Hospital, Sichuan Science and Technology Department

Acute myeloid leukemia

 

 

Recruiting

4

136

 

Homoharringtonine combined with cytarabine and Peg-Dox and recombinant human granulocyte colony-stimulating factor ;Decitabine、Homoharringtonine combined with cytarabine and recombinant human granulocyte colony-stimulating factor

Department of Hematology, Xinqiao Hospital, Army Medical University; Department of Hematology, Xinqiao Hospital, Army Medical University, Clinical key foundation of Xinqiao Hospital of Army Military Medical University

myelodysplastic syndrome with excess blasts

 

 

Recruiting

4

96

 

Serenixol, Dexcitabine, Cytarabine, Aclamycin, Homoharringtonine, Demethoxydaunorubicin, Granulocyte colony stimulating factor

Hebei Provincial Hospital of Traditional Chinese Medicine; Hebei Provincial Hospital of Traditional Chinese Medicine, None

Myelodysplastic syndrome & Acute myeloid leukemia

 

 

Recruiting

3

100

RoW

Azacitidine combined HHT, Azacitidine+HHT, Azacitidine regimen, Azacitidine group

Shandong Provincial Hospital

Myelodysplastic Syndromes,Acute Myeloid Leukemia

06/22

12/22

Recruiting

3

162

RoW

VEN combined with azacitidine plus homoharringtonine, VEN combined with azacitidine

Nanfang Hospital of Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Shenzhen Hospital of Southern Medical University, Peking University Shenzhen Hospital, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Southern Medical University, China, First People's Hospital of Chenzhou, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Guangxi Medical University

Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine

12/22

12/23

Recruiting

3

81

RoW

Homoharringtonine, venetoclax, Cytarabine, G-CSF, Vindesine, Daunorubicin, cyclophosphamide, Dexamethasone, L-ASP

First Affiliated Hospital of Zhejiang University

ETP-ALL

03/26

03/27

Recruiting

3

876

RoW

HVA, VA, Standard Chemotherapy

Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou First People's Hospital, Guangdong Second Provincial General Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, First Affiliated Hospital of Guangxi Medical University, Dongguan People's Hospital, First People's Hospital of Foshan, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Shenzhen Hospital of Southern Medical University, Affiliated Hospital of Guangdong Medical University, People's Hospital of Guangxi, First People's Hospital of Chenzhou, Hunan Provincial People's Hospital, Ganzhou City People's Hospital, First Affiliated Hospital of Gannan Medical University

Newly Diagnosed Acute Myeloid Leukemia With High Risk

06/26

12/26

Not yet recruiting

3

176

 

Homoharringtonine 2mg/m2/d, qd, intramuscular injection or intravenous drip, d1~d5; Cytarabine 100mg/m2/d, q12h, subcutaneous injection or intravenous drip, qd, d1~d5, Aclarubicin 12mg/m2/d, intravenous injection, d1~d5, venetoclax 100mg d2, 200mg d3, 300mg d4~d10, qd, oral ;Daunorubicin 60mg/ m2/d, intravenous injection, qd, d1~3; Ara-C 100mg/ m2/d, intravenous injection, qd or subcutaneous injection, two times, 12 hours apart, d1~d7

First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Medical College of Zhejiang University, Zhejiang Provincial Clinical Research Center For Hematological disorders

acute myeloid leukemia

 

 

Recruiting

2/3

60

RoW

Venetoclax, VEN, Homoharringtonine, HHT, Cytarabine

The First Affiliated Hospital of Soochow University

Acute Myeloid Leukemia

03/25

03/28

Not yet recruiting

2/3

610

 

ETP/near-ETP T-ALL chemotherapy; nonETP-T-ALL-Das Group chemotherapy with dasatinib; nonETP-T-ALL-HHT Group chemotherapy with homoharringtonine

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Self-funded

T-cell Acute Lymphoblastic Leukemia

 

 

Completed

2

180

 

1. Consolidation therapy with DA regimen: Intravenous injection daunorubicin (45mg/m2/day) from day 1 through day 3, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;2. Consolidation therapy with HA regimen: Intravenous injection Homoharringtonine (4mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5 ;3. Consolidation therapy with EA regimen: Intravenous injection Etoposide (100mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;4. Consolidation therapy with MA regimen: Intravenous injection Mitoxanetrone (7mg/m2/day) from day 1 through day 3, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;5. Consolidation therapy with TA regimen: Intravenous injection Topotecan (1.25mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;6. Consolidation therapy with AA regimen: Intravenous injection Aclarubicin (20mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;7. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR. ;1. Consolidation therapy with DA regimen: Intravenous injection daunorubicin (45mg/m2/day) from day 1 through day 3, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;2. Consolidation therapy with HA regimen: Intravenous injection Homoharringtonine (4mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;3. Consolidation therapy with EA regimen: Intravenous injection Etoposide (100mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;4. Consolidation therapy with MA regimen: Intravenous injection Mitoxanetrone (7mg/m2/day) from day 1 through day 3, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;5. Consolidation therapy with TA regimen: Intravenous injection Topotecan (1.25mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;6. Consolidation therapy with AA regimen: Intravenous injection Aclarubicin (20mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;7. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR.

Department of Hematology, the Second Affiliated Hospital of Dalian Medical University.; Level of the institution：, LiaoNing Project for Medicine Peak Construction (No.201112;2011-2013). 200,000 Yuan.

acute myelogenous leukemia

 

 

Active, not recruiting

2

40

RoW

Quizartinib, AC220, Omacetaxine Mepesuccinate Injection, homoharringtonine

The University of Hong Kong

AML, FLT3-ITD Mutation

10/20

10/21

Recruiting

2

30

RoW

Venetoclax；Azacitidine；Homoharringtonine

The First Affiliated Hospital with Nanjing Medical University

Secondary Acute Myeloid Leukemia

09/23

09/25

Recruiting

2

500

RoW

Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT

Children's Hospital of Soochow University

AML, Childhood, Acute Myeloid Leukemia

12/28

12/29

Recruiting

2

50

RoW

Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF

First Affiliated Hospital of Zhejiang University

Acute T Lymphpblastic Leukemia/Lymphoma

06/26

06/28

2

60

RoW

daunorubicin, Venetoclax, cytarabine, azacitidine, Homoharringtonine, Idarubicin

Institute of Hematology & Blood Diseases Hospital, China

AML

Recruiting

1/2

50

 

homoharringtonine plus venetoclax

Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University, Clinical Research Program of Nanfang Hospital, Southern Medical University

Actue meyloid leukemia

 

 

Completed

1/2

24

US

Omacetaxine Mepesuccinate, Ceflatonin, Cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(R)]- (9CI), CGX-635, HHT, homoharringtonine, Synribo, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

M.D. Anderson Cancer Center

Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome

09/24

09/24

Completed

1

120

 

Induction therapy with combination of all-trans retinoic acid and homoharringtonine. Consolidation therapy after complete response with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin/idarubicin. Consolidation therapy with combination of cytarabine and daunorubicin/idarubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin homoharringtonine. Consolidation therapy with combination of cytarabine and daunorubicin and/or homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid,arsenic trioxide and daunorubicin/idarubicin. Consolidation therapy with combination of cytarabine and daunorubicin/idarubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Ministry of Health funding

Adult patients with acute promyelocytic leukemia

 

 

Not yet recruiting

1

9

 

Cladribine + Homoharringtonine + cytarabine + Granulocyte stimulating factor + Chidamide

Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences; Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, No

AML

 

 

1

US

Omacetaxine, Venetoclax

University of Illinois at Chicago

Relapsed or Refractory Hematologic Malignancies

07/25

07/25

Not yet recruiting

1

60

 

homoharringtonine combined with Venetoclax was used to induce remission chemotherapy and consolidation chemotherapy, specifically Homoharringtonine 2mg, d 1-14, intravenous drip once a day; Venetoclax 400mg, d 1-14, oral administration once a day.

The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, Self selected topic (self raised)

AML and high-risk MDS

 

 

Recruiting

N/A

40

 

Nebulized inhalation of homoharringtonine+Basic treatment ;Basic treatment

Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, In-house subject

Novel Coronavirus Pneumonia (COVID-19)

 

 

Not yet recruiting

N/A

100

 

HIA scheme ;HAD scheme

Shanxi Bethune Hospital of Shanxi Medical University; Shanxi Bethune Hospital of Shanxi Medical University, Self financing

Acute myeloid leukemia

 

 

Recruiting

N/A

30

RoW

Azacitidine and homoharringtonine

Fourth Military Medical University, Qilu Hospital of Shandong University, Taian City Central Hospital, The Affiliated Hospital of Qingdao University, The Second Hospital of Hebei Medical University, Children's Hospital of Hebei Province

JMML

01/23

01/25

Not yet recruiting

N/A

400

 

HAD scheme ;CHG scheme ;DHAD scheme ;DCHG scheme

Shanxi Bethune Hospital of Shanxi Medical University; Shanxi Bethune Hospital of Shanxi Medical University, Self financing

Acute myeloid leukemia

 

 

Not yet recruiting

N/A

20

RoW

Selinexor, Homoharringtonine, Cytarabine, Aclacinomycin, Granulocyte Colony-Stimulating Factor, Decitabine, Azacitidine

The First Affiliated Hospital of Soochow University

Relapsed/Refractory AML

06/24

06/24

Recruiting

N/A

40

 

Venetoclax in combination with high dose of Decitabine and Homoharringtonine (DEC3-VEN-HHT) as therapy

Tai'an City Central Hospital; The Affiliated Tai'an City Central Hospital of Qingdao University, None

Newly diagnosed patient acute myeloid leukemia with RUNX1 / RUNX1TI, CBFB/MYH11 mutation

 

 

Not yet recruiting

N/A

90

NA

Mitoxantrone hydrochloride liposome injection, Cytarabine, Homoharringtonine, Venetoclax

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Acute Myeloid Leukemia

10/26

12/26

Recruiting

N/A

15

 

homoharringtonine combined with azacytidine and venetoclax

The First Hospital of China Medical University; The First Hospital of China Medical University, Self-financing

Acute myeloid leukemia